Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:SNN
CUSIPN/A
Phone44-20-7401-7646
Debt
Debt-to-Equity Ratio0.31
Current Ratio2.13
Quick Ratio1.05
Price-To-Earnings
Trailing P/E Ratio19.47
Forward P/E Ratio19.41
P/E Growth3.04
Sales & Book Value
Annual Sales$4.77 billion
Price / Sales3.39
Cash Flow$2.8971 per share
Price / Cash12.73
Book Value$10.61 per share
Price / Book3.48
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees15,933
Outstanding Shares437,360,000
Market Cap$16.20 billion
Smith & Nephew (NYSE:SNN) Frequently Asked Questions
What is Smith & Nephew's stock symbol?
Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?
Smith & Nephew declared a None dividend on Wednesday, February 14th. Investors of record on Friday, April 6th will be paid a dividend of $0.444 per share on Wednesday, May 9th. The ex-dividend date is Thursday, April 5th. View Smith & Nephew's Dividend History.
How were Smith & Nephew's earnings last quarter?
Smith & Nephew plc (NYSE:SNN) announced its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.39 by $0.59. View Smith & Nephew's Earnings History.
What price target have analysts set for SNN?
6 equities research analysts have issued 12-month price targets for Smith & Nephew's shares. Their predictions range from $42.00 to $42.00. On average, they expect Smith & Nephew's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Smith & Nephew.
What is the consensus analysts' recommendation for Smith & Nephew?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Smith & Nephew.
What are Wall Street analysts saying about Smith & Nephew stock?
Here are some recent quotes from research analysts about Smith & Nephew stock:
- 1. According to Zacks Investment Research, "Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world " (9/19/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted a day of investor meetings with Smith & Nephew’s new CEO Cowdy, EVP Business Development and Corporate Affairs, and Andrew Swift, Head of IR, and came away incrementally more confident in SNN’s ability to deliver top-line growth ultimately supporting share momentum through H2/18 and beyond. Unsurprisingly, investor interest was focused on Mr. Nawana’s vision for the company and plans to unlock shareholder value with a renewed focus on execution and top-line growth. Specifically, a strategy of driving above market growth via a focus on key/differentiated products and a customer-centric shift in company culture and organizational structure, which ultimately should drive long-term margin expansion." (8/6/2018)
Who are some of Smith & Nephew's key competitors?
Some companies that are related to Smith & Nephew include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Avanos Medical (AVNS), Wright Medical Group (WMGI), Halyard Health (HYH), CONSORT Med PLC/S (CSRMY), Sientra (SIEN) and Invacare (IVC).
Who are Smith & Nephew's key executives?
Smith & Nephew's management team includes the folowing people:
- Mr. Graham Timothy Baker, CFO & Exec. Director (Age 50)
- Mr. Namal Nawana, CEO & Exec. Director (Age 47)
- Mr. Mark Gladwell, Pres of Global Operations (Age 43)
- Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 45)
- Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
Has Smith & Nephew been receiving favorable news coverage?
News stories about SNN stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Smith & Nephew earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Smith & Nephew.
Who are Smith & Nephew's major shareholders?
Smith & Nephew's stock is owned by a number of of retail and institutional investors. Top institutional investors include Cambiar Investors LLC (1.38%), Nuance Investments LLC (0.49%), Fisher Asset Management LLC (0.48%), Bank of America Corp DE (0.36%), Millennium Management LLC (0.23%) and Glenmede Trust Co. NA (0.22%).
Which major investors are selling Smith & Nephew stock?
SNN stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Bank of America Corp DE, Millennium Management LLC, Renaissance Technologies LLC, US Bancorp DE, Nuance Investments LLC, BlackRock Inc. and Employees Retirement System of Texas.
Which major investors are buying Smith & Nephew stock?
SNN stock was purchased by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Dalton Greiner Hartman Maher & Co., Glenmede Trust Co. NA, Cox Capital Co LLC, CIBC Private Wealth Group LLC, Dean Capital Investments Management LLC, Sei Investments Co. and AMP Capital Investors Ltd.
How do I buy shares of Smith & Nephew?
Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Smith & Nephew's stock price today?
One share of SNN stock can currently be purchased for approximately $36.88.
How big of a company is Smith & Nephew?
Smith & Nephew has a market capitalization of $16.20 billion and generates $4.77 billion in revenue each year. The medical equipment provider earns $767 million in net income (profit) each year or $1.90 on an earnings per share basis. Smith & Nephew employs 15,933 workers across the globe.
How can I contact Smith & Nephew?
Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]
MarketBeat Community Rating for Smith & Nephew (NYSE SNN)
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
